{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:55:36Z","timestamp":1781358936525,"version":"3.54.1"},"reference-count":52,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2018.4563","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T08:11:55Z","timestamp":1537171915000},"source":"Crossref","is-referenced-by-count":9,"title":["Prognostic value and potential function of splicing events in prostate adenocarcinoma"],"prefix":"10.3892","author":[{"given":"Zhi-Guang","family":"Huang","sequence":"first","affiliation":[{"name":"Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Quan","family":"He","sequence":"additional","affiliation":[{"name":"Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng-Nan","family":"Mo","sequence":"additional","affiliation":[{"name":"Guangxi Collaborative Innovation Center for Biomedicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2018,9,17]]},"reference":[{"key":"key20200713185318_b1-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrurol.2014.91","article-title":"Prostate cancer in young men: An important clinical entity","volume":"11","author":"Salinas","year":"2014","journal-title":"Nat Rev Urol"},{"key":"key20200713185318_b2-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.suc.2015.05.001","article-title":"Prostate Cancer Screening and the Associated Controversy","volume":"95","author":"Tabayoyong","year":"2015","journal-title":"Surg Clin North Am"},{"key":"key20200713185318_b3-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key20200713185318_b4-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"key20200713185318_b5-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10552-007-9083-8","article-title":"Quantifying the role of PSA screening in the US prostate cancer mortality decline","volume":"19","author":"Etzioni","year":"2008","journal-title":"Cancer Causes Control"},{"key":"key20200713185318_b6-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"key20200713185318_b7-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1586\/14737159.2015.1110022","article-title":"Prognostic and predictive biomarkers in prostate cancer","volume":"15","author":"Kontos","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"key20200713185318_b8-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"890697","DOI":"10.1155\/2014\/890697","article-title":"Novel tools for prostate cancer prognosis, diagnosis, and follow-up","volume":"2014","author":"Dimakakos","year":"2014","journal-title":"BioMed Res Int"},{"key":"key20200713185318_b9-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00432-013-1377-5","article-title":"Detection of circulating tumor cells in different stages of prostate cancer","volume":"139","author":"Thalgott","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20200713185318_b10-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/aja.2013.6","article-title":"Urinary biomarkers for prostate cancer: A review","volume":"15","author":"Hessels","year":"2013","journal-title":"Asian J Androl"},{"key":"key20200713185318_b11-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-1-62703-980-2_4","article-title":"Alternative pre-mRNA splicing","volume":"1126","author":"Wagner","year":"2014","journal-title":"Methods Mol Biol"},{"key":"key20200713185318_b12-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2012.07.083","article-title":"Function of alternative splicing","volume":"514","author":"Kelemen","year":"2013","journal-title":"Gene"},{"key":"key20200713185318_b13-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.biocel.2014.06.013","article-title":"Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells","volume":"54","author":"Krause","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"key20200713185318_b14-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4103\/1008-682X.127825","article-title":"The role of mRNA splicing in prostate cancer","volume":"16","author":"Lapuk","year":"2014","journal-title":"Asian J Androl"},{"key":"key20200713185318_b15-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1038\/onc.2013.284","article-title":"Mechanisms of the androgen receptor splicing in prostate cancer cells","volume":"33","author":"Liu","year":"2014","journal-title":"Oncogene"},{"key":"key20200713185318_b16-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12672-014-0177-y","article-title":"The link between androgen receptor splice variants and castration-resistant prostate cancer","volume":"5","author":"Sprenger","year":"2014","journal-title":"Horm Cancer"},{"key":"key20200713185318_b17-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jprot.2013.04.007","article-title":"Innovations in proteomic profiling of cancers: Alternative splice variants as a new class of cancer biomarker candidates and bridging of proteomics with structural biology","volume":"90","author":"Omenn","year":"2013","journal-title":"J Proteomics"},{"key":"key20200713185318_b18-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.canlet.2017.02.016","article-title":"Prognostic alternative mRNA splicing signature in non-small cell lung cancer","volume":"393","author":"Li","year":"2017","journal-title":"Cancer Lett"},{"key":"key20200713185318_b19-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1093\/bioinformatics\/bts452","article-title":"SpliceSeq: A resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts","volume":"28","author":"Ryan","year":"2012","journal-title":"Bioinformatics"},{"key":"key20200713185318_b20-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/onc.2015.318","article-title":"Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes","volume":"35","author":"Sveen","year":"2016","journal-title":"Oncogene"},{"key":"key20200713185318_b21-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/wrna.1222","article-title":"Splicing factor mutations and cancer","volume":"5","author":"Yoshida","year":"2014","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"key20200713185318_b22-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12185-012-1182-y","article-title":"Splicing factor mutations in myelodysplasia","volume":"96","author":"Ogawa","year":"2012","journal-title":"Int J Hematol"},{"key":"key20200713185318_b23-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/jmcb\/mjv027","article-title":"Deregulation of splicing factors and breast cancer development","volume":"7","author":"Silipo","year":"2015","journal-title":"J Mol Cell Biol"},{"key":"key20200713185318_b24-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nsmb1209","article-title":"The gene encoding the splicing factor SF2\/ASF is a proto-oncogene","volume":"14","author":"Karni","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"key20200713185318_b25-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1101\/gad.237206.113","article-title":"An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth","volume":"28","author":"Adler","year":"2014","journal-title":"Genes Dev"},{"key":"key20200713185318_b26-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"D1018","DOI":"10.1093\/nar\/gkv1288","article-title":"TCGASpliceSeq a compendium of alternative mRNA splicing in cancer","volume":"44","author":"Ryan","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"key20200713185318_b27-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"key20200713185318_b28-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/humu.21609","article-title":"SpliceAid 2: A database of human splicing factors expression data and RNA target motifs","volume":"33","author":"Piva","year":"2012","journal-title":"Hum Mutat"},{"key":"key20200713185318_b29-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1109\/TVCG.2014.2346248","article-title":"UpSet: Visualization of intersecting sets","volume":"20","author":"Lex","year":"2014","journal-title":"IEEE Trans Vis Comput Graph"},{"key":"key20200713185318_b30-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3390\/biom5020893","article-title":"RNA-Binding Proteins: Splicing Factors and Disease","volume":"5","author":"Fredericks","year":"2015","journal-title":"Biomolecules"},{"key":"key20200713185318_b31-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/nar\/gkx1306","article-title":"Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer","volume":"46","author":"He","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"key20200713185318_b32-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00439-017-1792-9","article-title":"RNA splicing and splicing regulator changes in prostate cancer pathology","volume":"136","author":"Munkley","year":"2017","journal-title":"Hum Genet"},{"key":"key20200713185318_b33-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ctrv.2015.12.003","article-title":"AR-V7 and prostate cancer: The watershed for treatment selection?","volume":"43","author":"Ciccarese","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"key20200713185318_b34-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"6863","DOI":"10.1158\/0008-5472.CAN-17-1397","article-title":"PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer","volume":"77","author":"Couture","year":"2017","journal-title":"Cancer Res"},{"key":"key20200713185318_b35-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12032-015-0593-z","article-title":"Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts","volume":"32","author":"Hernandez","year":"2015","journal-title":"Med Oncol"},{"key":"key20200713185318_b36-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1038\/onc.2013.360","article-title":"The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells","volume":"33","author":"Cappellari","year":"2014","journal-title":"Oncogene"},{"key":"key20200713185318_b37-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13059-016-1121-y","article-title":"The incredible complexity of RNA splicing","volume":"17","author":"Robert","year":"2016","journal-title":"Genome Biol"},{"key":"key20200713185318_b38-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/jnci\/djt174","article-title":"Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial","volume":"105","author":"Brasky","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"key20200713185318_b39-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/ijc.28203","article-title":"Plasma phospholipid fatty acids, dietary fatty acids and prostate cancer risk","volume":"133","author":"Bassett","year":"2013","journal-title":"Int J Cancer"},{"key":"key20200713185318_b40-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1940-6207.CAPR-13-0349","article-title":"Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance","volume":"7","author":"Moreel","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"key":"key20200713185318_b41-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"15135","DOI":"10.18632\/oncotarget.7715","article-title":"P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth","volume":"7","author":"Gang","year":"2016","journal-title":"Oncotarget"},{"key":"key20200713185318_b42-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"26558","DOI":"10.1074\/jbc.M109.063255","article-title":"Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells","volume":"285","author":"Xiao","year":"2010","journal-title":"J Biol Chem"},{"key":"key20200713185318_b43-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3109\/1061186X.2015.1108325","article-title":"Mitochondria-targeted drug delivery system for cancer treatment","volume":"24","author":"Chen","year":"2016","journal-title":"J Drug Target"},{"key":"key20200713185318_b44-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"e1221555","DOI":"10.1080\/2162402X.2016.1221555","article-title":"Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy","volume":"5","author":"Goltz","year":"2016","journal-title":"OncoImmunology"},{"key":"key20200713185318_b45-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13148-016-0270-x","article-title":"PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy","volume":"8","author":"Holmes","year":"2016","journal-title":"Clin Epigenetics"},{"key":"key20200713185318_b46-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/15592294.2016.1241931","article-title":"CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients","volume":"11","author":"Meller","year":"2016","journal-title":"Epigenetics"},{"key":"key20200713185318_b47-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"R70","DOI":"10.1186\/gb-2013-14-7-r70","article-title":"Transcriptome analysis of human tissues and cell lines reveals one dominant transcript per gene","volume":"14","author":"Gonz\u00e0lez-Porta","year":"2013","journal-title":"Genome Biol"},{"key":"key20200713185318_b48-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/humu.22561","article-title":"Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era","volume":"35","author":"Soussi","year":"2014","journal-title":"Hum Mutat"},{"key":"key20200713185318_b49-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/0008-5472.CAN-13-2876","article-title":"Androgen receptor splice variants determine taxane sensitivity in prostate cancer","volume":"74","author":"Thadani-Mulero","year":"2014","journal-title":"Cancer Res"},{"key":"key20200713185318_b50-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/sj.onc.1201498","article-title":"Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer","volume":"15","author":"Carstens","year":"1997","journal-title":"Oncogene"},{"key":"key20200713185318_b51-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1261\/rna.057919.116","article-title":"Splicing-factor alterations in cancers","volume":"22","author":"Anczuk\u00f3w","year":"2016","journal-title":"RNA"},{"key":"key20200713185318_b52-ijo-53-06-2473","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-biochem-060614-034316","article-title":"Mechanisms and regulation of alternative Pre-mRNA splicing","volume":"84","author":"Lee","year":"2015","journal-title":"Annu Rev Biochem"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T19:00:34Z","timestamp":1594666834000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2018.4563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,17]]},"references-count":52,"URL":"https:\/\/doi.org\/10.3892\/ijo.2018.4563","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,17]]}}}